MedWatch

Genmab strikes deal with German biotech company

Denmark’s Genmab has signed a new million-dollar deal in the immuno-oncology field with Germany’s Biontech – a company which recently signed a highly lucrative deal with Eli Lilly.

Photo: Genmab, PR

The Danish-based biotech group Genmab has signed a commercial agreement concerning its DuoBody technology with Germany’s Biontech in the immuno-oncology field, Genmab writes in an announcement.

The deal will see the two companies jointly research, develop and commercialize bispecific antibody products using Genmab’s DuoBody technology platform.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs